ARTELO BIOSCIENCES INC ARTL 深 滬
等待開盤 10-22 09:30:00 美东时间
3.45
-0.430
-11.08%
華盛通- 最 高3.90
- 今 開3.90
- 成交量 10.44万股
- 最 低 3.37
- 昨 收 3.88
- 總市值 188.65万
- 52周最高 28.60
- 市盈率 靜 --
- 換手率 19.09%
- 52周最低 3.37
- 委 比 89.02%
- 總股本 54.68万
- 歷史最高 450.00
- 量 比 1.33
- 振 幅 13.66%
- 歷史最低 3.37
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences Enters Cooperation Agreement with Farb
An update from Artelo Biosciences ( ($ARTL) ) is now available. On October 15, ...
10-18 05:03
Artelo Biosciences Reports Phase 1 And 2 Data For ART26.12 And ART27.13, Highlighting Safety And Significant Weight Gain In Cancer Anorexia Trial
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and
10-15 21:18
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
Artelo Biosciences announced positive interim Phase 1 and 2 data for its FABP5 inhibitor ART26.12 and dual cannabinoid agonist ART27.13. ART26.12 demonstrated safety, predictable linear exposure, and dosing flexibility in fed or fasted states. ART27.13 showed substantial weight gain and activity improvements in Phase 2 cancer anorexia trials, with a favorable safety profile. These findings support further development of both compounds for treatin...
10-15 13:15
Artelo Biosciences Prices $2.0M Public Offering
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for
09-30 22:11
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SciSparc (NASDAQ:SPRC) stock increased by 40.8% to $6.28 during Tuesda...
09-30 20:09
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
.Artelo Biosciences announced interim data from its Phase 2 CAReS study showing that ART27.13, a novel cannabinoid agonist, significantly improved weight, lean body mass, and daily activity in patients with cancer anorexia-cachexia syndrome (CACS). Patients on the highest dose (1300 µg) achieved a 6% weight gain over 12 weeks, while those on placebo lost an additional 5%. ART27.13 demonstrated a favorable safety profile, with mostly mild to moder...
09-29 12:30
Artelo Biosciences Completes Stock Offering with Over-Allotment
Artelo Biosciences ( ($ARTL) ) has provided an update. Artelo Biosciences, Inc....
09-16 04:57
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
Artelo Biosciences announced the publication of new preclinical data on ART12.11, its CBD:TMP cocrystal. The study, conducted with Western Ontario University, showed ART12.11 significantly outperformed CBD alone in reducing stress-induced depression and anxiety symptoms and achieved superior oral bioavailability. Key findings include enhanced efficacy, improved bioavailability, and mechanistic insights into its effects on endocannabinoid and sero...
09-10 12:30
D. Boral Capital Downgrades Artelo Biosciences to Hold
D. Boral Capital analyst Jason Kolbert downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
09-08 19:21
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced its public offering of 640,924 shares of common stock at $4.40 per share and pre-funded warrants for up to 40,894 shares at $4.399 per warrant. The offering is expected to raise approximately $3.0 million in gross proceeds. Underwriters have a 45-day option to purchase an additional 102,272 shares. The offering is expected to close on September 5, 2025, subject to customary c...
09-04 12:37
